Anti-HCV Antibody Among Newly Diagnosed HIV Patients in Ughelli, a Suburban Area of Delta State Nigeria

Overview

Journal Afr Health Sci

Date 2016 Mar 10

PMID 26957959

Citations 5

Authors

Ogbodo Ekene Newton

Otue Akpevwe Oghene

Iheanyi Omezuruike Okonko

Affiliations

Soon will be listed here.

Abstract

Background: Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) share common routes of infection and as such, co-infection is expected. Co-infection of the two viruses is of great medical importance as it determines the effect of drugs used for treatment at various stages.

Objective: This interplay between HIV and HCV sets the tone for the objective of this study which is to ascertain the seroprevalence of HCV among newly diagnosed HIV patients in Ughelli, a suburban area of Delta State, Nigeria.

Methods: A total of 200 newly diagnosed HIV-positive patients were recruited for this study. Each of the sera was tested for anti-HCV antibody using SWE-life HCV ultra rapid test strip. Appropriate questionnaires were used to ascertain other important information which include social behaviour such as whether the patients were MSM (males), IDU, tattoo and/or have received blood transfusion in the past.

Results: The prevalence of HCV among the study population was determined to be 15.0%. A higher seroprevalence was observed among females (16.5%) than in males (13.0%). A higher seroprevalence was also observed among age groups >26 years (16.0%) than in age-groups 14-25 years (13.0%) and 2-13 years (0.0%). Of the 7 patients with tattoos, 1(14.3%) tested positive for HCV compared to 29(15.0%) with no tattoos. We found no significant correlation with transfusion, intravenous drug use (IDU), men that have sex with men (MSM), tattooing and the seroprevalence of HCV. However, significant correlation existed with age, sex and HCV prevalence.

Conclusion: This study reports a 15.0% seroprevalence of HCV among newly diagnosed HIV patients and that is alarmingly well above several other studies done in the past in Nigeria and other countries of sub-Saharan Africa. Planned preven tion, screening, and treatment are needed to reduce further transmission and morbidity. Future studies involving HCV-RNA assays are needed.

Citing Articles

Hepatitis B and C Virus Co-Infection and Their Association With Liver Disease in Persons With HIV in Nigeria.

Odeghe E, Oyeleke G, Odofin M, Duguru M, Davwar P, Nyam D J Int Assoc Provid AIDS Care. 2024; 23:23259582241292511.

PMID: 39469965 PMC: 11528674. DOI: 10.1177/23259582241292511.

Detection of hepatitis C virus among HIV patients in Port Harcourt, Rivers State.

Baeka G, Oloke J, Opaleye O Afr Health Sci. 2022; 21(3):1010-1015.

PMID: 35222562 PMC: 8843266. DOI: 10.4314/ahs.v21i3.8.

Increased liver injury in patients with chronic hepatitis and IgG directed against hepatitis E virus.

Sevede D, Doumbia M, Kouakou V, Djehiffe V, Pineau P, Dosso M EXCLI J. 2019; 18:955-961.

PMID: 31762722 PMC: 6868915. DOI: 10.17179/excli2019-1827.

Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda.

Umutesi J, Simmons B, Makuza J, Dushimiyimana D, Mbituyumuremyi A, Uwimana J BMC Infect Dis. 2017; 17(1):315.

PMID: 28464899 PMC: 5414306. DOI: 10.1186/s12879-017-2422-9.

Hepatitis, HIV and Ebola: light at the end of the tunnel.

Tumwine J Afr Health Sci. 2016; 15(3):i-iv.

PMID: 26958003 PMC: 4765446. DOI: 10.4314/ahs.v15i3.1.

References

Rockstroh J, Bhagani S . Managing HIV/hepatitis C co-infection in the era of direct acting antivirals. BMC Med. 2013; 11:234. PMC: 4225604. DOI: 10.1186/1741-7015-11-234. View

Parboosing R, Paruk I, Lalloo U . Hepatitis C virus seropositivity in a South African Cohort of HIV co-infected, ARV naïve patients is associated with renal insufficiency and increased mortality. J Med Virol. 2008; 80(9):1530-6. DOI: 10.1002/jmv.21262. View

Rockstroh J, Mocroft A, Soriano V, Tural C, Losso M, Horban A . Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005; 192(6):992-1002. DOI: 10.1086/432762. View

Lesi O, Kehinde M, Oguh D, Amira C . Hepatitis B and C virus infection in Nigerian patients with HIV/AIDS. Niger Postgrad Med J. 2007; 14(2):129-33. View

Laurent C, Bourgeois A, Mpoudi M, Butel C, Mpoudi-Ngole E, Delaporte E . HIV and hepatitis C virus coinfection, Cameroon. Emerg Infect Dis. 2007; 13(3):514-6. PMC: 2725885. DOI: 10.3201/eid1303.061069. View

Mehta S, Cox A, Hoover D, Wang X, Mao Q, Ray S . Protection against persistence of hepatitis C. Lancet. 2002; 359(9316):1478-83. DOI: 10.1016/S0140-6736(02)08435-0. View

Tong M, Reikes A, Co R . Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995; 332(22):1463-6. DOI: 10.1056/NEJM199506013322202. View

. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 2000; 6(1):35-47. View

Nunez M, Lana R, Mendoza J, Martin-Carbonero L, Soriano V . Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001; 27(5):426-31. DOI: 10.1097/00126334-200108150-00002. View

10.

Chen S, Morgan T . The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006; 3(2):47-52. PMC: 1415841. DOI: 10.7150/ijms.3.47. View

11.

Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G . Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol. 2005; 42(5):615-24. DOI: 10.1016/j.jhep.2005.03.003. View

12.

Alter M, Margolis H, Krawczynski K, Judson F, Mares A, ALEXANDER W . The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992; 327(27):1899-905. DOI: 10.1056/NEJM199212313272702. View

13.

Ayele W, Nokes D, Abebe A, Messele T, Dejene A, Enquselassie F . Higher prevalence of anti-HCV antibodies among HIV-positive compared to HIV-negative inhabitants of Addis Ababa, Ethiopia. J Med Virol. 2002; 68(1):12-7. DOI: 10.1002/jmv.10164. View

14.

Sulkowski M, Moore R, Mehta S, Chaisson R, Thomas D . Hepatitis C and progression of HIV disease. JAMA. 2002; 288(2):199-206. DOI: 10.1001/jama.288.2.199. View

15.

Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P . Viral hepatitis and HIV co-infection. Antiviral Res. 2009; 85(1):303-15. DOI: 10.1016/j.antiviral.2009.10.021. View

16.

Alter M, Nainan O, McQuillan G, Gao F, Moyer L, Kaslow R . The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341(8):556-62. DOI: 10.1056/NEJM199908193410802. View

17.

Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H . Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000; 356(9244):1800-5. DOI: 10.1016/s0140-6736(00)03232-3. View

18.

Ogunro P, Adekanle D, Fadero F, Ogungbamigbe T, Oninla S . Prevalence of anti-hepatitis C virus antibodies in pregnant women and their offspring in a tertiary hospital in Southwestern Nigeria. J Infect Dev Ctries. 2009; 1(3):333-6. View

19.

Volf V, Marx D, Pliskova L, Sumegh L, celko A . A survey of hepatitis B and C prevalence amongst the homeless community of Prague. Eur J Public Health. 2007; 18(1):44-7. DOI: 10.1093/eurpub/ckm072. View

20.

Spradling P, Richardson J, Buchacz K, Moorman A, Finelli L, Bell B . Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996-2007. J Acquir Immune Defic Syndr. 2009; 53(3):388-96. DOI: 10.1097/QAI.0b013e3181b67527. View